PIFT: PBC Induced Fatigue Treated With Thiamine
Study Details
Study Description
Brief Summary
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterised by destruction of the intrahepatic bile ducts leading to liver inflammation and fibrosis, and ultimately liver cirrhosis and end-stage liver disease. More than 50% of patients with PBC suffer from chronic fatigue, and approximately 20% suffer from severe fatigue with negative impact on their quality of life. Although fatigue is a large problem in patients with PBC, no effective treatments are available.
A Danish intervention study have shown that high dose oral thiamine (Vitamin B1) were effective in treating chronic fatigue in patients with inflammatory bowel disease. In this study, only few and minor adverse events to thiamine treatment were observed. Although the precise mechanism of work remains unknown, the investigators see no reason that this cannot be transferred topatients with PBC. Hence, the investigators aim to conduct a study investigating the use of oral thiamine in chronic fatigued patients with PBC.
The study will be conducted as a double-blinded, placebo-controlled, randomised, crossover trial including 36 patients with PBC and with a higher fatigue level than in the general population for more than six months. The patients will be randomised into one of two 3x4 weeks setups; 1) thiamine for four weeks followed by four weeks washout and finally four weeks of placebo or 2) placebo for four weeks followed by four weeks washout and finally four weeks of thiamine. The primary endpoint is to investigate the fatigue-level before and after treatment with thiamine and placebo using every patient as their own control. Fatigue-level will be measured using international validated questionnaires. The doses of thiamine are calculated based on the patient gender and weight. All patients will be included in the outpatient clinic at the Department of Hepatology and Gastroenterology at Aarhus University Hospital.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Thiamine-Placebo 12 weeks: 4 weeks with Thiamine, 4 weeks wash-out, 4 weeks placebo Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day. |
Drug: Thiamine
Tablets. 300mg/tablet. Dosage depends on gender and weight
Drug: Placebo
Tablets. Same number of tablets as Thiamine
|
| Other: Placebo-Thiamine 12 weeks: 4 weeks placebo, 4 weeks wash-out, 4 weeks with Thiamine Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day. |
Drug: Thiamine
Tablets. 300mg/tablet. Dosage depends on gender and weight
Drug: Placebo
Tablets. Same number of tablets as Thiamine
|
Outcome Measures
Primary Outcome Measures
- Fatigue [After 4 weeks active treatment]
Change in levels of fatigue measured by the Primary biliary cholangitis-40 (PBC-40) fatigue domain. The fatigue domain measures the severity of fatigue on a scale from 11-55, where 55 is maximun fatigue. A change in PBC-40 fatigue domain of 5 points or more is regarded as a clinical relevant change.
Secondary Outcome Measures
- Disease-specific Quality of Life [Week 4, 8 and 12]
Changes in Health-related Quality of life, measured by the disease specific Primary biliary Cholangitis-40 (PBC-40).
- Health-related Quality of Life [Week 4, 8 and 12]
Changes in Health-related Quality of Life, measured by the generic EQ-5D-5L tool (mainly the VAS-scale from 0-100, where 100 is best).
- Fatigue [Week 8 and 12]
Change in levels of fatigue measured by the Primary biliary cholangitis-40 (PBC-40) fatigue domain. The fatigue domain measures the severity of fatigue on a scale from 11-55, where 55 is maximun fatigue. A change in PBC-40 fatigue domain of 5 points or more is regarded as a clinical relevant change.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
PBC for more than 3 months
-
PBC-40 fatigue score >32
-
Fatigued for at least 6 months
Exclusion Criteria:
-
Comorbidity that can explain fatigue
-
Non-compliant patients
-
Pregnancy
-
Expected surgical interventions during the study period
-
Chronic kidney disease (eGFR<60)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark | Aarhus N | Region Midtjylland | Denmark | 8200 |
Sponsors and Collaborators
- Henning Grønbæk
- Aarhus University Hospital
- Hospitalsapoteket Region Midtjylland
- GCP-unit at Aarhus University Hospital, Aarhus, Denmark
- Region Hovedstadens Apotek
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PIFT AU